ExodusPoint Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

ExodusPoint Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.55M	Sell	17,775 -57,366	-76%	-$5.58M	0.01%	868
2025 Q4	$8.04M	Buy	+75,141	New	+$7.97M	0.06%	319
2024 Q1	–	Sell	-40,197	Closed	-$1.85M	–	1906
2023 Q4	$1.85M	Sell	40,197 -112,246	-74%	-$3.54M	0.01%	607
2023 Q3	$3.5M	Buy	152,443 +136,762	+872%	+$3.06M	0.03%	475
2023 Q2	$259K	Sell	15,681 -37,977	-71%	-$685K	﹤0.01%	1599
2023 Q1	$957K	Buy	+53,658	New	+$1.35M	0.01%	1150
2022 Q1	–	Sell	-15,475	Closed	-$154K	–	2612
2021 Q4	$154K	Buy	15,475 +3,874	+33%	+$43.5K	﹤0.01%	1880
2021 Q3	$152K	Sell	11,601 -3,343	-22%	-$51.1K	﹤0.01%	1834
2021 Q2	$293K	Buy	+14,944	New	+$310K	﹤0.01%	1758
2020 Q3	–	Sell	-13,483	Closed	-$301K	–	2168
2020 Q2	$301K	Buy	+13,483	New	+$263K	0.01%	1321
2019 Q2	–	Sell	-19,596	Closed	-$537K	–	1299
2019 Q1	$537K	Buy	+19,596	New	+$563K	0.04%	311

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ExodusPoint Capital Management's RYTM Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 76% in Q1 2026, selling an estimated $5.58M and leaving 17,775 shares worth $1.55M. The position accounts for 0.01% of the portfolio, ranked #868.

ExodusPoint Capital Management first reported a position in RYTM in Q1 2019 and has held it in 11 quarters since. The position peaked at $8.04M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

ExodusPoint Capital Management held 17,775 shares of Rhythm Pharmaceuticals worth $1.55M as of Q1 2026.
ExodusPoint Capital Management sold 57,366 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $5.58M.
Rhythm Pharmaceuticals made up 0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #868 holding.
ExodusPoint Capital Management first reported a position in Rhythm Pharmaceuticals in Q1 2019 and has held it in 11 quarters since.
ExodusPoint Capital Management's Rhythm Pharmaceuticals position peaked at $8.04M in Q4 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.